Lagociclovir is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine. It has high oral bioavailability in humans and potent activity against HBV.

Anti-HBV compound Oral administration of MIV-210 (20 or 60 mg/kg; body weight/day) induced a rapid virological response in chronically infected woodchucks, reducing serum WHV DNA levels by 4.75 log10 and 5.72 log10, respectively, in 2 weeks. MIV-210 at 20 or 60 mg/kg/day reduced the liver WHV DNA load 200- to 2,500-fold from pretreatment levels and, importantly, led to a 2.0 log10 drop in the hepatic content of WHV covalently closed circular DNA. Further, a daily dose of 10 mg/kg decreased the serum WHV load 400-fold after 4 weeks of treatment, and a dose of 5 mg/kg/day was sufficient to maintain this antiviral effect during the following 6-week period.

92562-88-4

C10H12FN5O3

269.23

MIV-210;Lagociclovir

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years